Question 1

Does BNP Paribas Financial Markets own ADCT stock?

Accepted Answer

Yes. As of its Q2 2026 13F, BNP Paribas Financial Markets holds 652,849 shares of ADCT (Adc Therapeutics), worth $698,548.

Question 2

How many shares of ADCT does BNP Paribas Financial Markets own?

Accepted Answer

As of its Q2 2026 13F, BNP Paribas Financial Markets holds 652,849 shares of ADCT (Adc Therapeutics).

Question 3

What is BNP Paribas Financial Markets' ADCT position worth?

Accepted Answer

As of its Q2 2026 13F, BNP Paribas Financial Markets' ADCT position is worth $698,548.

Question 4

Is BNP Paribas Financial Markets buying or selling ADCT?

Accepted Answer

In Q2 2026, BNP Paribas Financial Markets reduced its ADCT position by 207,642 shares (-24.1%).

Question 5

When did BNP Paribas Financial Markets first buy ADCT?

Accepted Answer

BNP Paribas Financial Markets first reported ADCT in its Q3 2022 13F and has listed it in 8 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Decreased	652,849	-24.1%	$698,548	0.0%	$1.07	0
2026-Q1	Increased	860,491	+3.6%	$3.2M	0.0%	$3.75	27
2025-Q4	Increased	830,903	+20.7%	$2.9M	0.0%	$3.53	31
2025-Q3	Increased	688,471	+15.2%	$2.8M	0.0%	$4.00	30
2025-Q2	Decreased	597,792	-13.6%	$1.6M	0.0%	$2.68	0
2025-Q1	Decreased	692,078	-3.4%	$975,830	0.0%	$1.41	0
2024-Q4	New	716,668	-	$1.4M	0.0%	$1.99	35
2022-Q4	Exited	0	-100.0%	$0	0.0%	$3.84	0
2022-Q3	New	726	-	$3,499	0.0%	$4.82	21

ADCT9 quarters

ADCT
9 quarters